+271.2%
LIN vs MRNA
+786.4%
-515.2%
-32.6%
Performance
Returns, benchmark comparison, and relative performance.
Performance by timeframe
Returns for 10y.
| Period | Portfolio | MRNA | Excess | Alpha |
|---|---|---|---|---|
| 1D | -1.4% | -2.2% | +0.7% | -1.4% |
| 7D | -4.4% | -12.7% | +8.3% | -4.1% |
| 30D | +0.5% | -20.7% | +21.1% | +0.9% |
| 3M | +4.8% | +46.3% | -41.4% | +3.5% |
| 6M | -0.1% | +305.2% | -305.3% | -6.5% |
| YTD | +19.1% | +561.2% | -542.2% | +8.5% |
| 1Y | +24.8% | +772.1% | -747.3% | +12.1% |
| 3Y | +28.0% | +147.0% | -119.0% | +19.3% |
| 5Y | +62.0% | -26.1% | +88.0% | +55.3% |
| All | +271.2% | +786.4% | -515.2% | +224.5% |
Cumulative growth
Daily Returns
Daily percentage return beside MRNA.
Daily Out/Under-Performance
Portfolio return minus MRNA return. Positive bars indicate outperformance.
Daily Alpha
Portfolio daily return minus β × MRNA return. Early observations use the first valid beta; later observations use the trailing beta estimated for each date.
Cumulative Out/Under-Performance
Relative wealth over 10y: compounded portfolio wealth divided by compounded MRNA wealth, less one. Both series rebase at the selected span's start.
Cumulative Alpha
Compounded beta-adjusted residual returns apply the first valid beta to early observations, then the trailing beta ending on each date.
Updating return analytics…
10y analysis · Full analysis span regression · 6 months rolling